CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 164 filers reported holding CLOVIS ONCOLOGY INC in Q4 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $173,000 | -39.3% | 145,400 | -8.2% | 0.00% | -33.3% |
| Q2 2022 | $285,000 | -18.6% | 158,350 | -8.5% | 0.00% | 0.0% |
| Q1 2022 | $350,000 | -23.1% | 173,050 | +3.0% | 0.00% | -25.0% |
| Q4 2021 | $455,000 | -48.0% | 168,050 | -14.4% | 0.00% | -50.0% |
| Q3 2021 | $875,000 | -26.5% | 196,300 | -4.4% | 0.01% | -20.0% |
| Q2 2021 | $1,191,000 | -14.1% | 205,300 | +4.0% | 0.01% | -16.7% |
| Q1 2021 | $1,386,000 | -9.9% | 197,450 | -38.4% | 0.01% | -14.3% |
| Q4 2020 | $1,538,000 | -15.5% | 320,450 | +2.6% | 0.01% | -30.0% |
| Q3 2020 | $1,821,000 | -15.7% | 312,300 | -2.4% | 0.02% | -20.0% |
| Q2 2020 | $2,159,000 | +8.9% | 319,900 | +2.7% | 0.02% | +8.7% |
| Q1 2020 | $1,982,000 | -38.2% | 311,600 | +1.3% | 0.02% | -11.5% |
| Q4 2019 | $3,207,000 | +120.9% | 307,630 | -16.7% | 0.03% | +116.7% |
| Q3 2019 | $1,452,000 | -51.1% | 369,375 | +85.1% | 0.01% | -47.8% |
| Q2 2019 | $2,967,000 | +118.5% | 199,550 | +264.8% | 0.02% | +130.0% |
| Q1 2019 | $1,358,000 | – | 54,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,997,826 | $10,834,000 | 0.69% |
| Ikarian Capital, LLC | 1,112,669 | $3,016,000 | 0.45% |
| Versant Venture Management, LLC | 101,855 | $276,000 | 0.15% |
| Virtus ETF Advisers LLC | 60,836 | $165,000 | 0.06% |
| EMFO, LLC | 21,500 | $58,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| PINNACLE ASSOCIATES LTD | 706,336 | $1,914,000 | 0.03% |
| XTX Topco Ltd | 20,920 | $57,000 | 0.03% |
| State of Wyoming | 25,419 | $69,000 | 0.03% |